Question

Is stem cell therapy for Complex Regional Pain Syndrome worth it?

Current evidence does not support buying cell therapy as routine CRPS care after other treatments have failed. The most defensible access is through a well-designed registered clinical trial with independent oversight, transparent costs and no promise of pain or functional improvement. Participation must remain integrated with specialist multidisciplinary CRPS care.

Medical review statusPending clinical sign-offLast evidence update: 2026-08-05Methodology and editorial standards
Clinical review team: Dr Kamelia Milcheva, Hematologist · Dr Vadym Uvarov, Board-Certified Physician · Hepatobiliary Surgeon · Candidate of Medical SciencesEditorial responsibility: StemCellAtlas research teamEducational information only. This page does not provide medical advice, diagnosis or a treatment recommendation.

How stem cells are studied for Complex Regional Pain Syndrome

Complex regional pain syndrome (CRPS) is a chronic pain condition that may follow injury or surgery and can involve sensory, autonomic, motor and trophic changes in a limb. Management is individualised and commonly includes rehabilitation, pain treatment and psychological support, with specialist interventions in selected cases. Mesenchymal stromal cells (MSCs) and other cell approaches are experimental; proposed inflammatory or neural mechanisms have not established clinical benefit. The registry table on this page lists relevant studies and their current recruitment status.

Am I a candidate? → · Complex Regional Pain Syndrome: full overview → · Complex Regional Pain Syndrome cost → · Cost →

Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.

Sources & further reading

Explore all sections · Data & downloads

Compare cell-therapy evidence, registered studies and published price observations.

StemCellAtlas is a source-first research and cost-planning guide. It separates registry and regulator evidence from heterogeneous commercial observations.

Request written information